Merck’s Stock Struggles Amid Market Surges
In Rahway, New Jersey, Merck & Co., Inc. (MRK) stands as a significant player in the healthcare sector. With a market capitalization of $252.4 billion, the company offers a variety of health solutions, including prescription medicines, vaccines, biologic therapies, animal health products, and consumer care items. These products are marketed both directly and through partnerships.
Stock Performance: A Year of Disappointment
Over the last year, Merck’s shares have lagged behind the overall market. The stock has fallen by 21.1%, while the S&P 500 Index ($SPX) has increased by nearly 20.9%. In 2025, MRK shares have seen only slight changes compared to the SPX, which has risen by 1.9% year-to-date (YTD).
Comparative Analysis with iShares U.S. Pharmaceuticals ETF
When compared to the iShares U.S. Pharmaceuticals ETF (IHE), Merck’s struggles are even clearer. The ETF has experienced gains of approximately 7.6% over the past year and shows a 5.3% increase on a YTD basis, far surpassing Merck’s modest performance.
Challenges Impacting Merck’s Performance
Several factors contribute to MRK’s decline, including falling demand for its HPV vaccine Gardasil in China, pricing pressures in the U.S., and competition from generic drugs affecting its diabetes treatments (Januvia/Janumet) globally. Concerns are growing about Merck’s non-oncology growth, particularly as the patent for Keytruda will expire in 2028. However, increased competition is motivating the company to enhance its product pipeline.
Quarterly Results Highlight Growth
On February 4, MRK released its Q4 earnings. The adjusted earnings per share (EPS) of $1.72 exceeded Wall Street’s expectations of $1.69. The company’s revenue reached $15.62 billion, surpassing forecasts of $15.55 billion. Looking ahead to fiscal 2025, MRK anticipates full-year adjusted EPS between $8.88 and $9.03, alongside revenue predictions ranging from $64.1 billion to $65.6 billion.
Analysts Maintain Positive Outlook
For fiscal 2024, which closes in December 2024, analysts expect Merck’s EPS to grow by 404.6% to $7.62 on a diluted basis. Impressively, Merck has beaten earnings estimates in every one of the last four quarters. Out of 25 analysts tracking MRK stock, the consensus rating is a “Strong Buy,” consisting of 18 “Strong Buy” ratings and seven “Holds.”
While this outlook is slightly less optimistic compared to previous months, when 19 analysts recommended a “Strong Buy,” it still reflects a positive sentiment.
On January 30, Leerink Partners analyst Daina Graybosch reaffirmed a “Buy” rating for MRK with a price target of $118, suggesting an upside of 18.2% from current prices. The average price target among analysts is $125.95, indicating a 26.2% premium to Merck’s current value. A particularly optimistic price target of $168 implies a potential increase of 68.4%.
On the date of publication, Neha Panjwani did not hold any positions in the securities mentioned. The information provided in this article is for informational purposes only. For further details, please refer to the Barchart Disclosure Policy here.
More news from Barchart
The views and opinions expressed in this article are solely those of the author and do not necessarily represent the views of Nasdaq, Inc.
